Clonal alteration of breast cancer receptors between primary ductal carcinoma in situ (DCIS) and corresponding local events

European Journal of Cancer

Volumn 50, Issue 3, 2014, Pages 517-524

  Karlsson, E ^a,b   Sandelin, K ^c   Appelgren, J ^d   Zhou, W ^e   Jirstrom K ^f   Bergh, J ^a   Warnberg F ^g  

^a KAROLINSKA INSTITUTE   (Sweden)

^b CENTRAL HOSPITAL   (Sweden)

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^d KARLSTAD UNIVERSITY   (Sweden)

^e UPPSALA UNIVERSITY   (Sweden)

^f LUND UNIVERSITY   (Sweden)

^g UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Breast cancer; DCIS; Ductal carcinoma in situ; ER; HER2; Hormonal receptor; Human epidermal growth factor receptor 2; Oestrogen receptor; PR; Progesterone receptor

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR;

ADULT; ARTICLE; CANCER RADIOTHERAPY; CANCER RECURRENCE; CARCINOMA IN SITU; CONTROLLED STUDY; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; INTRADUCTAL CARCINOMA; MAJOR CLINICAL STUDY; MIDDLE AGED; PRIORITY JOURNAL; TUMOR GROWTH; TUMOR INVASION;

BREAST CANCER; DCIS; DUCTAL CARCINOMA IN SITU; ER; HER2; HORMONAL RECEPTOR; HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2; OESTROGEN RECEPTOR; PR; PROGESTERONE RECEPTOR;

BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, INTRADUCTAL, NONINFILTRATING; CLONE CELLS; COHORT STUDIES; FEMALE; HUMANS; MIDDLE AGED; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TUMOR MARKERS, BIOLOGICAL;

EID: 84893691711     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2013.10.020     Document Type: Article

References (40)

1. E.S. Wai, M.L. Lesperance, C.S. Alexander, P.T. Truong, P. Moccia, and M. Culp et al. Predictors of local recurrence in a population-based cohort of women with ductal carcinoma in situ treated with breast conserving surgery alone Ann Surg Oncol 18 1 2011 119 124 [Epub 2010/07/21]
2. N. Bijker, P. Meijnen, J.L. Peterse, J. Bogaerts, I. Van Hoorebeeck, and J.P. Julien et al. Breast-conserving treatment with or without radiotherapy in ductal carcinoma-in-situ: ten-year results of European Organisation for Research and Treatment of Cancer randomized phase III trial 10853 - a study by the EORTC Breast Cancer Cooperative Group and EORTC Radiotherapy Group J Clin Oncol 24 21 2006 3381 3387 [Epub 2006/06/28]
3. S.O. Emdin, B. Granstrand, A. Ringberg, K. Sandelin, L.G. Arnesson, and H. Nordgren et al. SweDCIS: Radiotherapy after sector resection for ductal carcinoma in situ of the breast. Results of a randomised trial in a population offered mammography screening Acta Oncol 45 5 2006 536 543 [Epub 2006/07/26]
4. J.P. Julien, N. Bijker, I.S. Fentiman, J.L. Peterse, V. Delledonne, and P. Rouanet et al. Radiotherapy in breast-conserving treatment for ductal carcinoma in situ: first results of the EORTC randomised phase III trial 10853. EORTC Breast Cancer Cooperative Group and EORTC Radiotherapy Group Lancet 355 9203 2000 528 533 [Epub 2000/02/22]
5. E. Provenzano, J.L. Hopper, G.G. Giles, G. Marr, D.J. Venter, and J.E. Armes Biological markers that predict clinical recurrence in ductal carcinoma in situ of the breast Eur J Cancer 39 5 2003 622 630 [Epub 2003/03/12]
6. A. Ringberg, L. Anagnostaki, H. Anderson, I. Idvall, and M. Ferno Cell biological factors in ductal carcinoma in situ (DCIS) of the breast-relationship to ipsilateral local recurrence and histopathological characteristics Eur J Cancer 37 12 2001 1514 1522 [Epub 2001/08/17]
7. C. Liedtke, K. Broglio, S. Moulder, L. Hsu, S.W. Kau, and W.F. Symmans et al. Prognostic impact of discordance between triple-receptor measurements in primary and recurrent breast cancer Ann Oncol 20 12 2009 1953 1958 [Epub 2009/07/15]
8. L.S. Lindstrom, E. Karlsson, U.M. Wilking, U. Johansson, J. Hartman, and E.K. Lidbrink et al. Clinically used breast cancer markers such as estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 are unstable throughout tumor progression J Clin Oncol 30 21 2012 2601 2608 [Epub 2012/06/20]
9. N. Niikura, J. Liu, N. Hayashi, E.A. Mittendorf, Y. Gong, and S.L. Palla et al. Loss of human epidermal growth factor receptor 2 (HER2) expression in metastatic sites of HER2-overexpressing primary breast tumors J Clin Oncol 30 6 2012 593 599 [Epub 2011/11/30]
10. C. Kamby, B.B. Rasmussen, and B. Kristensen Oestrogen receptor status of primary breast carcinomas and their metastases. Relation to pattern of spread and survival after recurrence Br J Cancer 60 2 1989 252 257 [Epub 1989/08/01]
11. G. Curigliano, V. Bagnardi, G. Viale, L. Fumagalli, N. Rotmensz, and G. Aurilio et al. Should liver metastases of breast cancer be biopsied to improve treatment choice? Ann Oncol 22 10 2011 2227 2233 [Epub 2011/02/24]
12. A.M. Thompson, L.B. Jordan, P. Quinlan, E. Anderson, A. Skene, and J.A. Dewar et al. Prospective comparison of switches in biomarker status between primary and recurrent breast cancer: the Breast Recurrence In Tissues Study (BRITS) Breast Cancer Res 12 6 2010 R92 [Epub 2010/11/10]
13. E. Amir, N. Miller, W. Geddie, O. Freedman, F. Kassam, and C. Simmons et al. Prospective study evaluating the impact of tissue confirmation of metastatic disease in patients with breast cancer J Clin Oncol 30 6 2012 587 592 [Epub 2011/11/30]
14. U. Wilking, E. Karlsson, L. Skoog, T. Hatschek, E. Lidbrink, and G. Elmberger et al. HER2 status in a population-derived breast cancer cohort: discordances during tumor progression Breast Cancer Res Treat 125 2 2011 553 561 [Epub 2010/07/16]
15. L. Holmberg, H. Garmo, B. Granstrand, A. Ringberg, L.G. Arnesson, and K. Sandelin et al. Absolute risk reductions for local recurrence after postoperative radiotherapy after sector resection for ductal carcinoma in situ of the breast J Clin Oncol 26 8 2008 1247 1252 [Epub 2008/02/06]
16. W. Zhou, K. Jirstrom, C. Johansson, R.M. Amini, C. Blomqvist, and O. Agbaje et al. Long-term survival of women with basal-like ductal carcinoma in situ of the breast: a population-based cohort study BMC Cancer 10 2010 653 [Epub 2010/12/02]
17. T. Foukakis, G. Astrom, L. Lindstrom, T. Hatschek, and J. Bergh When to order a biopsy to characterise a metastatic relapse in breast cancer Ann Oncol 23 Suppl. 10 2012 x349 x353 [Epub 2012/09/26]
18. L. Pusztai, G. Viale, C.M. Kelly, and C.A. Hudis Estrogen and HER-2 receptor discordance between primary breast cancer and metastasis Oncologist 15 11 2010 1164 1168 [Epub 2010/11/03]
19. J. Kononen, L. Bubendorf, A. Kallioniemi, M. Barlund, P. Schraml, and S. Leighton et al. Tissue microarrays for high-throughput molecular profiling of tumor specimens Nat Med 4 7 1998 844 847 [Epub 1998/07/14]
20. J. Torhorst, C. Bucher, J. Kononen, P. Haas, M. Zuber, and O.R. Kochli et al. Tissue microarrays for rapid linking of molecular changes to clinical endpoints Am J Pathol 159 6 2001 2249 2256 [Epub 2001/12/06]
21. F. Warnberg, R.M. Amini, M. Goldman, and K. Jirstrom Quality aspects of the tissue microarray technique in a population-based cohort with ductal carcinoma in situ of the breast Histopathology 53 6 2008 642 649 [Epub 2008/12/17]
22. A. Zidan, J.S. Christie Brown, D. Peston, and S. Shousha Oestrogen and progesterone receptor assessment in core biopsy specimens of breast carcinoma J Clin Pathol 50 1 1997 27 29 [Epub 1997/01/01]
23. I.J. Fidler, and M.L. Kripke Metastasis results from preexisting variant cells within a malignant tumor Science 197 4306 1977 893 895 [Epub 1977/08/26]
24. M. Gerlinger, A.J. Rowan, S. Horswell, J. Larkin, D. Endesfelder, and E. Gronroos et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing N Engl J Med 366 10 2012 883 892 [Epub 2012/03/09]
25. A.E. Karnoub, A.B. Dash, A.P. Vo, A. Sullivan, M.W. Brooks, and G.W. Bell et al. Mesenchymal stem cells within tumour stroma promote breast cancer metastasis Nature 449 7162 2007 557 563 [Epub 2007/10/05]
26. P. Farmer, H. Bonnefoi, P. Anderle, D. Cameron, P. Wirapati, and V. Becette et al. A stroma-related gene signature predicts resistance to neoadjuvant chemotherapy in breast cancer Nat Med 15 1 2009 68 74 [Epub 2009/01/06]
27. G. Finak, N. Bertos, F. Pepin, S. Sadekova, M. Souleimanova, and H. Zhao et al. Stromal gene expression predicts clinical outcome in breast cancer Nat Med 14 5 2008 518 527 [Epub 2008/04/29]
28. I. Martin-Padura, G. Gregato, P. Marighetti, P. Mancuso, A. Calleri, and C. Corsini et al. The white adipose tissue used in lipotransfer procedures is a rich reservoir of CD34+ progenitors able to promote cancer progression Cancer Res 72 1 2012 325 334 [Epub 2011/11/05]
29. A.C. Vargas, A.E. Reed, N. Waddell, A. Lane, L.E. Reid, and C.E. Smart et al. Gene expression profiling of tumour epithelial and stromal compartments during breast cancer progression Breast Cancer Res Treat 135 1 2012 153 165 [Epub 2012/06/22]
30. A. Goldhirsch, W.C. Wood, A.S. Coates, R.D. Gelber, B. Thurlimann, and H.J. Senn Strategies for subtypes - dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011 Ann Oncol 22 8 2011 1736 1747 [Epub 2011/06/29]
31. A. Goldhirsch, E.P. Winer, A.S. Coates, R.D. Gelber, M. Piccart-Gebhart, and B. Thurlimann et al. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013 Ann Oncol 24 9 2013 2206 2223 [Epub 2013/08/07]
32. A.A. Muggerud, M. Hallett, H. Johnsen, K. Kleivi, W. Zhou, and S. Tahmasebpoor et al. Molecular diversity in ductal carcinoma in situ (DCIS) and early invasive breast cancer Mol Oncol 4 4 2010 357 368 [Epub 2010/07/29]
33. R.E. Roses, E.C. Paulson, A. Sharma, J.E. Schueller, H. Nisenbaum, and S. Weinstein et al. HER-2/neu overexpression as a predictor for the transition from in situ to invasive breast cancer Cancer Epidemiol Biomarkers Prev 18 5 2009 1386 1389 [Epub 2009/04/23]
34. S. Harada, R. Mick, R.E. Roses, H. Graves, H. Niu, and A. Sharma et al. The significance of HER-2/neu receptor positivity and immunophenotype in ductal carcinoma in situ with early invasive disease J Surg Oncol 104 5 2011 458 465 [Epub 2011/05/11]
35. N. Liao, G.C. Zhang, Y.H. Liu, X.R. Li, M. Yao, and F.P. Xu et al. HER2-positive status is an independent predictor for coexisting invasion of ductal carcinoma in situ of the breast presenting extensive DCIS component Pathol Res Pract 207 1 2011 1 7 [Epub 2010/11/26]
36. E.K. Latta, S. Tjan, R.K. Parkes, and F.P. O'Malley The role of HER2/neu overexpression/amplification in the progression of ductal carcinoma in situ to invasive carcinoma of the breast Mod Pathol 15 12 2002 1318 1325 [Epub 2002/12/14]
37. D.C. Allred, G.M. Clark, R. Molina, A.K. Tandon, S.J. Schnitt, and K.W. Gilchrist et al. Overexpression of HER-2/neu and its relationship with other prognostic factors change during the progression of in situ to invasive breast cancer Hum Pathol 23 9 1992 974 979 [Epub 1992/09/01]
38. K. Kerlikowske, A.M. Molinaro, M.L. Gauthier, H.K. Berman, F. Waldman, and J. Bennington et al. Biomarker expression and risk of subsequent tumors after initial ductal carcinoma in situ diagnosis J Natl Cancer Inst 102 9 2010 627 637 [Epub 2010/04/30]
39. E. Rakovitch, S. Nofech-Mozes, W. Hanna, S. Narod, D. Thiruchelvam, and R. Saskin et al. HER2/neu and Ki-67 expression predict non-invasive recurrence following breast-conserving therapy for ductal carcinoma in situ Br J Cancer 106 6 2012 1160 1165 [Epub 2012/03/01]
40. A. Ringberg, H. Nordgren, S. Thorstensson, I. Idvall, H. Garmo, and B. Granstrand et al. Histopathological risk factors for ipsilateral breast events after breast conserving treatment for ductal carcinoma in situ of the breast - results from the Swedish randomised trial Eur J Cancer 43 2 2007 291 298 [Epub 2006/11/23]